Noninvasive Real-Time Glucose Monitoring Is in the Near Future
Diabetes Technology & Therapeutics · 2024
DOI: 10.1089/dia.2024.0009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2024. Verfasst von Irl B Hirsch und 2 weiteren Autor:innen. Beteiligte Einrichtung: UW Medicine Diabetes Institute, School of Medicine, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Blood Glucose Self-Monitoring, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Since the introduction of continuous glucose monitoring (CGM) technology, developers have rigorously researched the feasibility of creating a noninvasive glucose monitoring device. In a recent pilot study, investigators reported a strong correlation between glucose values obtained from novel noninvasive monitoring device (GWave) values to venous and capillary glucose measurements. Research Design and Methods: We investigated whether the level of accuracy observed in the pilot study could be reproduced in a larger cohort, using a smaller third-generation manufacturable device (Gen III GWave) containing a standardized sensor chip that can be mass produced for commercial use. The evaluation assessed concordance with capillary blood glucose, reproducibility between two Gen III devices, and accuracy during insulin-induced hypoglycemia.
Results
Assessment of samples from 75 subjects (type 2 diabetes, n = 6; type 1 diabetes, n = 28; nondiabetic pregnant subjects, n = 10; and nondiabetic, n = 31) showed that 97% of values were in Zone A with 3% in Zone B of the Clarke Error Grid, with a mean absolute relative difference of 6.7% from reference blood glucose. Comparison between two independent Gen III GWave devices demonstrated reproducibility between the sensors ( R 2 = 0.95), with 100% of values within Zone A. In the hypoglycemia assessment, measurements from the Gen III sensor tightly followed the capillary glucose measurements down to 42 mg/dL (2.3 mmol/L), whereas the CGM measurements from two different CGM only converged with the GWave and capillary glucose readings after 90 min of decreasing glucose levels.
Conclusion
Our results show promise as potentially the first noninvasive technology. Future studies will focus on larger number of people in all glucose ranges. Real-time noninvasive blood glucose monitoring is possible using GWave technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UW Medicine Diabetes Institute, School of Medicine, University of Washington, Seattle, Washington, USA.
- Division of Endocrinology, Diabetes, and Metabolism, Sheba Medical Center, Ramat Gan, Israel.
- Department of Immunology and Regenerative Biology, The Weizmann Institute of Science, Rehovot, Israel.
ORCID-Profile: Irl B Hirsch
Zitieren
APA
Hirsch, I. B., Tirosh, A., & Navon, A. (2024). Noninvasive Real-Time Glucose Monitoring Is in the Near Future. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2024.0009
Vancouver
Hirsch IB, Tirosh A, Navon A. Noninvasive Real-Time Glucose Monitoring Is in the Near Future. Diabetes Technology & Therapeutics. 2024. doi:10.1089/dia.2024.0009
BibTeX
@article{Hirsch2024,
author = {Hirsch, Irl B and Tirosh, Amir and Navon, Ami},
title = {Noninvasive Real-Time Glucose Monitoring Is in the Near Future},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
doi = {10.1089/dia.2024.0009}
}
EUVIMED